Related Experiment Video
Updated: Jan 8, 2026
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
11.0K
Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study
Helmut Butzkueven1, Pamela Farr2, Serkan Ozakbas3
1Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Australia; MSBase Foundation, Alfred Centre, Melbourne, Australia.
Multiple Sclerosis and Related Disorders
|December 20, 2025
Summary
Ocrelizumab (OCR) shows significant long-term effectiveness in relapsing multiple sclerosis (RMS) patients in real-world settings. The study observed reduced relapses and disability progression, with high treatment persistence.
Area of Science:
- Neurology
- Immunology
- Clinical Trials
Background:
- Ocrelizumab (OCR) is a targeted therapy for relapsing multiple sclerosis (RMS).
- Real-world data is crucial for understanding long-term treatment effectiveness beyond clinical trials.
Purpose of the Study:
- To evaluate the long-term effectiveness and safety of ocrelizumab (OCR) in a real-world cohort of patients with relapsing multiple sclerosis (RMS).
- To assess outcomes including disability worsening, disease progression, and no evidence of disease activity (NEDA-3).
Main Methods:
- Prospective, longitudinal, observational cohort study (MSOCR-R) using the international MSBase registry.
- Inclusion of 1011 patients with RMS newly treated with OCR.
- Analysis of confirmed disability worsening (CDW), progression independent of relapses (PIRA), and NEDA-3 over a median follow-up of 3.4 years.
Main Results:
- Four-year probabilities for 24-week CDW and PIRA were 25.2% and 21.9%, respectively.
- Annualized relapse rate decreased significantly from 0.58 to 0.05 post-OCR initiation.
- Achieving NEDA-3 at 4 years was 39.7%, with 88.0% treatment persistence.
Conclusions:
- Ocrelizumab demonstrates strong real-world effectiveness in managing relapsing multiple sclerosis.
- First-line treatment with OCR was associated with superior clinical outcomes.
- The findings support OCR as a valuable therapeutic option for RMS patients.
More Related Videos
Related Concept Videos
01:11Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
133
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
133
01:16Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
380
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
380
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
179
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
179
01:27Bioavailability Study Design: Absolute Versus Relative Bioavailability
267
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
267